GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TriSalus Life Sciences Inc (NAS:TLSI) » Definitions » Return-on-Tangible-Asset

TriSalus Life Sciences (TriSalus Life Sciences) Return-on-Tangible-Asset : -255.60% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is TriSalus Life Sciences Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. TriSalus Life Sciences's annualized Net Income for the quarter that ended in Mar. 2024 was $-52.88 Mil. TriSalus Life Sciences's average total tangible assets for the quarter that ended in Mar. 2024 was $20.69 Mil. Therefore, TriSalus Life Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -255.60%.

The historical rank and industry rank for TriSalus Life Sciences's Return-on-Tangible-Asset or its related term are showing as below:

TLSI' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -293.85   Med: -162.05   Max: -77.87
Current: -293.85

During the past 3 years, TriSalus Life Sciences's highest Return-on-Tangible-Asset was -77.87%. The lowest was -293.85%. And the median was -162.05%.

TLSI's Return-on-Tangible-Asset is ranked worse than
97.11% of 866 companies
in the Medical Devices & Instruments industry
Industry Median: -2.745 vs TLSI: -293.85

TriSalus Life Sciences Return-on-Tangible-Asset Historical Data

The historical data trend for TriSalus Life Sciences's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TriSalus Life Sciences Return-on-Tangible-Asset Chart

TriSalus Life Sciences Annual Data
Trend Dec21 Dec22 Dec23
Return-on-Tangible-Asset
-77.87 -162.05 -257.86

TriSalus Life Sciences Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only -164.59 -319.88 -21.21 -497.02 -255.60

Competitive Comparison of TriSalus Life Sciences's Return-on-Tangible-Asset

For the Medical Devices subindustry, TriSalus Life Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TriSalus Life Sciences's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where TriSalus Life Sciences's Return-on-Tangible-Asset falls into.



TriSalus Life Sciences Return-on-Tangible-Asset Calculation

TriSalus Life Sciences's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-59.038/( (21.193+24.598)/ 2 )
=-59.038/22.8955
=-257.86 %

TriSalus Life Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-52.876/( (24.598+16.776)/ 2 )
=-52.876/20.687
=-255.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


TriSalus Life Sciences  (NAS:TLSI) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


TriSalus Life Sciences Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of TriSalus Life Sciences's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


TriSalus Life Sciences (TriSalus Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
6272 W. 91st Avenue, Westminster, CO, USA, 80031
TriSalus Life Sciences Inc is an oncology company integrating standard-of-care treatments and its investigational immunotherapeutic, SD-101, with disruptive Pressure Enabled Drug Delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. TriSalus is a commercial-stage medical device and Phase I clinical-stage pharmaceutical company.
Executives
Jodi Devlin officer: President, Therapeutics C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
James Alecxih officer: President, Device Technology C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Bryan F. Cox officer: Chief Scientific & Manufact. C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Kerry R Hicks director C/O HEALTHGRADES.COM, 44 UNION BLVD SUITE 600, LAKEOOD CO 80228
George Kelly Martin director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Jennifer Stevens officer: Chief Regulatory Officer C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Richard Marshak officer: Sr.VP, Corp. Dev. & Strategy C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Mary T Szela director, officer: CEO and President 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Anil K. Singhal director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Sean Murphy director, officer: Chief Financial Officer C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703
Arjun Jj Desai director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Steven C Katz officer: Chief Medical Officer C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Mats Wahlstrom director, 10 percent owner 500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401
Von Eschenbach Andrew C. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Equity Ab Frankenius 10 percent owner BOX 984, BORAS V7 SE-501 10